Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FORMaT trial for Mycobacterium abscessus pulmonary disease
2023-506575-99-00Phase 2Authorised
- Sponsor
- The University of Queensland
- Start
- Jan 2023
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 9
01
Overview
Phase 2 trial of clofazimine, tigecycline, clarithromycin, cilastatin, bedaquiline and 11 more in Mycobacterium abscessus lung disease, sponsored by The University of Queensland. Primary endpoints: Microbiologic culture conversion and Treatment tolerability. Planned start Jan 2023; status: authorised.
02
Drugs
clofaziminetigecyclineclarithromycincilastatinbedaquiline
03
Conditions
Mycobacterium abscessus lung disease
Beyond the preview
Go deeper on 2023-506575-99-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506575-99-00.